ClinicalTrials.gg
CompletedNCT03541174PRECISIONUpdated Mar 21, 2023Results posted

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

A Phase 3 interventional study of Aprocitentan 12.5 mg and Aprocitentan 25 mg in Resistant Hypertension, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 159 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
218th of 1,779
730 · median 100
Started
2018
with 98 others
Phase 3
202 of 2,031
9 open now
Registered
1,205th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 218th largest by enrollment of the 1,779 interventional ones that give a count, is one of 99 that started in 2018, is one of 202 in phase 3, and was the 1,205th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.

Read the detailed description

Participation in the study will be up to 68 weeks.

The study has 4 periods:

  1. Screening period
  2. Placebo run-in period
  3. Randomized treatment period
  4. Safety follow-up period

The screening period lasts between 4 and 12 weeks. It starts at the screening visit with the signing of the informed consent form (ICF) and ends the day before the participant enters the run-in period.

At least 4 weeks before the start of the run-in period, the background antihypertensive medication (except beta-blockers) of participants with a diagnosis of true resistant hypertension and having a mean trough sitting systolic blood pressure of equal to or greater than 140 mmHg measured by automated AOBPM will be standardized by switching to a fixed combination of a calcium channel blocker (amlodipine), an angiotensin receptor blocker (valsartan) and a diuretic (hydrochlorothiazide).

In case a beta-blocker is used as one of the background antihypertensive medications or for any other indication, this can be kept, with the provision that it has been initiated and the dose kept stable for at least 4 weeks prior to the screening visit and the dose kept stable until the end-of-treatment.

Following the screening period this study has a run-in period of 4 weeks. During this period, placebo will be administered in order to exclude potential placebo responders.

Following the run-in period eligible participants will enter the randomized treatment period. This period lasts for 48 weeks. It starts at randomization (i.e., Day 1 of the double-blind part) and ends at the end-of-treatment visit (i.e., at the end of the double-blind withdrawal part).

The randomized treatment period consists of 3 parts: Part 1 is double-blind, randomized, parallel-group and placebo-controlled and lasts 4 weeks. Part 2 is single-blind and single-arm and lasts for 32 weeks. Part 3 is a double-blind withdrawal, randomized, parallel-group and placebo-controlled and lasts for 12 weeks.

End-of treatment is at Week 48 (i.e., end of the double-blind withdrawal part). The safety follow-up starts on the day after the last dose of study treatment and ends 30 to 33 days after the last dose of study treatment.

03

Conditions studied

  • Resistant Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening period:

  • Signed and dated form (ICF) prior to any study-mandated procedure;
  • Male and female participants; 18 years (or year of country specific majority) or older;
  • Historical documentation in the participant's medical records on uncontrolled blood pressure despite at least 3 background antihypertensive medications within 1 year before screening visit;
  • Treated with at least 3 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit (Visit 1);
  • Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 140 mmHg measured by Automated Office Blood Pressure Measurement (AOBPM);
  • Women of are eligible only if the following applies:

    • Negative pregnancy test at screening and at baseline (i.e., before randomization);
    • Agreement to undertake pregnancy tests during the study and up to 30 days after randomized study treatment discontinuation;
    • Agreement to use methods of from Screening up to at least 30 days after randomized study treatment discontinuation.

Run-in period (RI):

  • Switched to the standardized background antihypertensive therapy at least 4 weeks before the first RI visit;
  • Mean trough SiSBP greater than or equal to140 mmHg as measured by AOBPM.

Randomization period:

  • Stable dose of the standardized background antihypertensive therapy for at least 1 week before the end of the RI period;
  • Mean trough SiSBP greater than or equal to 140 mmHg measured by AOBPM.

Exclusion criteria

Exclusion Criteria:

  • Apparent/pseudo Resistant Hypertension (RHT) due to white coat effect, medical inertia, poor therapeutic adherence, or secondary causes of hypertension (except sleep apnea);
  • Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg as measured by AOBPM at two different timepoints;
  • Pregnant or lactating participants;
  • unstable cardiac disease at screening or in the past in the opinion of the investigator (exclusion of participants with significant or potential unstable cardiac disease);
  • Severe renal insufficiency;
  • Any known factor, disease or clinically relevant medical or surgical conditions that, in the opinion of the investigator, might put the participant at risk, interfere with treatment compliance, study conduct or interpretation of the results.
  • Treatment with any medication which may affect blood pressure (BP) and/or treatment with high dose of loop diuretics (i.e., furosemide greater than 80 mg/day, or equivalent dosage of other loop diuretics).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
730 participants (actual)

Study arms

  • Experimental
    Aprocitentan 25 mg in Part 1 (double-blind)

    Participants will receive aprocitentan 25 mg, orally, once daily in the morning for 4 weeks.

    Drug: Aprocitentan 25 mg

  • Experimental
    Aprocitentan 12.5 mg in Part 1 (double-blind)

    Participants will receive aprocitentan 12.5 mg, orally, once daily in the morning for 4 weeks.

    Drug: Aprocitentan 12.5 mg

  • Placebo comparator
    Placebo in Part 1 (double-blind)

    Participants will receive placebo (matching aprocitentan), orally, once daily in the morning for 4 weeks.

    Drug: Placebo

  • Experimental
    Aprocitentan 25 mg in Part 2 (single-blind, single arm)

    After 4-weeks in the double-blind randomized part (Part 1), participants will received 25 mg aprocitentan, orally, once daily in the morning for 32 weeks.

    Drug: Aprocitentan 25 mg

  • Experimental
    Aprocitentan 25 mg in Part 3 (double-blind withdrawal)

    After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive aprocitentan 25 mg, orally, once daily in the morning for 12 weeks.

    Drug: Aprocitentan 25 mg

  • Placebo comparator
    Placebo in Part 3 (double-blind withdrawal)

    After 32-weeks in the single-blind, single-arm part (Part 2), participants will be re-randomized and receive placebo (matching aprocitentan), orally, once daily in the morning for 12 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement

    Changes from baseline to Week 4 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.

    Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)

Secondary outcomes

  1. Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement

    Changes from double-blind withdrawal baseline (Week 36) to Week 40 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.

    Time frame: Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40

  2. Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement

    Changes from baseline to Week 4 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. A negative change indicates a decrease in SiDBP from baseline.

    Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)

  3. Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring

    ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (baseline and Week 4) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve and divided by the time span. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.

    Time frame: Pre-dose Day 1 (Part 1 double-blind randomized baseline) and Week 4 (End of double-blind randomized part 1)

  4. Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure

    Changes from double-blind withdrawal (Week 36) to Week 40 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiDBP from baseline.

    Time frame: Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40

  5. Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring

    ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (the double-blind withdrawal baseline \[Week 36\] and the week 40) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.

    Time frame: From Week 36 (Part 3 double-blind-withdrawal baseline) and Week 40

07

Results

Posted Mar 21, 2023

Participant flow

The study was done from 18 June 2018 to 25 April 2022.

Part 1 Double-Blind
Participant flow — Part 1 Double-Blind
MilestoneAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Aprocitentan 25 mg in Part 2 (Single-blind)Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Started243243244000
Safety set243245242000
Completed232234238000
Not completed1196000
Withdrew: Adverse event652000
Withdrew: Withdrawal by subject221000
Withdrew: Other reasons323000
Part 2 Single-Blind
Participant flow — Part 2 Single-Blind
MilestoneAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Aprocitentan 25 mg in Part 2 (Single-blind)Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Started00070400
Completed00061300
Not completed0009100
Withdrew: Adverse event0002500
Withdrew: Lack of efficacy000100
Withdrew: Withdrawal by subject0001900
Withdrew: Lost to follow-up000800
Withdrew: Death000500
Withdrew: Pregnancy000100
Withdrew: Other reasons0003200
Part 3 Double-Blind Withdrawal
Participant flow — Part 3 Double-Blind Withdrawal
MilestoneAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Aprocitentan 25 mg in Part 2 (Single-blind)Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Started0000307307
Safety set0000310303
Completed0000288289
Not completed00001918
Withdrew: Adverse event000087
Withdrew: Withdrawal by subject000014
Withdrew: Lost to follow-up000001
Withdrew: Other reasons000096
Withdrew: Re-randomized in part 3, however no drug dispensed000010

Outcome measures

PrimaryChange From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement

Changes from baseline to Week 4 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.

Time frame:
Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement
mmHgAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement-15.26 (-17.36 to -13.17)-15.20 (-17.27 to -13.13)-11.47 (-13.57 to -9.38)
Statistical analysis
  • Aprocitentan 12.5 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · Mixed Models Analysis · p = 0.0042 (Mixed effects model for Repeated Measures: Change from baseline in SiSBP = baseline SiSBP + treatment + visit + treatment x visit + baseline x visit.) · Ls mean difference to placebo: -3.79 · 97.5% CI -6.76 to -0.82
  • Aprocitentan 25 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · Mixed Models Analysis · p = 0.0046 (Mixed effects model for Repeated Measures: Change from baseline in SiSBP = baseline SiSBP + treatment + visit + treatment x visit + baseline x visit.) · Ls mean difference to placebo: -3.73 · 97.5% CI -6.67 to -0.78
SecondaryChange From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement

Changes from double-blind withdrawal baseline (Week 36) to Week 40 in mean trough SiSBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiSBP from baseline.

Time frame:
Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40
Reported as:
Least squares mean · mmHg
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement
mmHgAprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Unattended Automated Office Blood Pressure Measurement-1.47 (-2.97 to 0.04)4.36 (2.87 to 5.85)
Statistical analysis
  • Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) vs Placebo in Part 3 (Double-blind Withdrawal) · Mixed Models Analysis · p = <0.0001 (Mixed effects model for Repeated Measures: Change from DB-WD baseline in SiSBP = DB-WD baseline SiSBP + stratum (randomized treatment in DB part) + treatment + visit + treatment x visit + DB-WD baseline x visit.) · Ls mean difference to placebo.: -5.82 · 95% CI -7.94 to -3.71
SecondaryChange From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement

Changes from baseline to Week 4 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. A negative change indicates a decrease in SiDBP from baseline.

Time frame:
Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement
mmHgAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)
Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure Measurement-10.43 (-11.58 to -9.27)-10.95 (-12.09 to -9.82)-6.48 (-7.63 to -5.33)
Statistical analysis
  • Aprocitentan 12.5 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · Mixed Models Analysis · p = <0.0001 (Mixed effects model for Repeated Measures: Change from baseline in SiDBP = baseline SiDBP + treatment + visit + treatment x visit + baseline x visit.) · Ls mean difference to placebo: -3.94 · 95% CI -5.57 to -2.31
  • Aprocitentan 25 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · Mixed Models Analysis · p = <0.0001 (Mixed effects model for Repeated Measures: Change from baseline in SiDBP = baseline SiDBP + treatment + visit + treatment x visit + baseline x visit.) · Ls mean difference to placebo: -4.47 · 95% CI -6.09 to -2.85
SecondaryChanges From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring

ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (baseline and Week 4) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve and divided by the time span. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.

Time frame:
Pre-dose Day 1 (Part 1 double-blind randomized baseline) and Week 4 (End of double-blind randomized part 1)
Reported as:
Least squares mean · mmHg
Changes From Baseline to Week 4 of Double-blind Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring
mmHgAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)
24-hour mean systolic blood pressure-6.73 (-8.20 to -5.26)-8.44 (-9.88 to -7.00)-2.55 (-4.00 to -1.10)
24-hour mean diastolic blood pressure-6.25 (-7.20 to -5.29)-7.74 (-8.67 to -6.80)-1.92 (-2.87 to -0.98)
Statistical analysis
  • Aprocitentan 12.5 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference to placebo: -4.18 · 95% CI -6.25 to -2.12
  • Aprocitentan 25 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference to placebo: -5.90 · 95% CI -7.94 to -3.85
  • Aprocitentan 12.5 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · ANCOVA · p = <0.0001 · Ls mean difference to placebo: -4.32 · 95% CI -5.66 to -2.98
  • Aprocitentan 25 mg in Part 1 (Double-blind) vs Placebo in Part 1 (Double-blind) · ANCOVA · p = <0.0001 · Ls mean: -5.81 · 95% CI -7.14 to -4.49
SecondaryChange From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure

Changes from double-blind withdrawal (Week 36) to Week 40 in mean trough SiDBP were analyzed using a mixed model. Participants had their blood pressure (BP) measured at the study site using the automated oscillometric sphygmomanometer (Microlife WatchBP® Office) which was provided to each site. BP was to be measured at trough (before taking the study treatment and SBAT). The BP assessment, participant preparation (e.g., arm selection, arm position, cuff size) was standardized and followed the American Heart Association guidelines / Canadian Education Program on Hypertension. The participant was resting undisturbed, alone (unattended) in a quiet place for 5 minutes at each visit. BP was measured at each visit with the same device, which recorded five sitting blood pressure readings (one per minute, the first value was excluded from the average). A negative change indicates a decrease in SiDBP from baseline.

Time frame:
Pre-dose Week 36 (Part 3 double-blind-withdrawal baseline) up to Week 40
Reported as:
Least squares mean · mmHg
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure
mmHgAprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Change From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in Trough Sitting Diastolic Blood Pressure (SiDBP) Measured by Unattended Automated Office Blood Pressure-0.52 (-1.54 to 0.50)4.67 (3.66 to 5.68)
Statistical analysis
  • Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) vs Placebo in Part 3 (Double-blind Withdrawal) · Mixed Models Analysis · p = <0.0001 (Mixed effects model for Repeated Measures: Change from DB-WD baseline in SiDBP = Double-blind withdrawal baseline SiDBP + stratum (randomized treatment in DB part) + treatment + visit + treatment x visit + Double-blind withdrawal baseline x visit.) · Ls mean difference to placebo: -5.19 · 95% CI -6.62 to -3.76
SecondaryChanges From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring

ABPM devices were provided to each site by the central blood pressure laboratory. On the first day after all visit assessments were performed, the ABPM device (Mobil-O-Graph NG) was fitted to the participant. The following day (i.e., second day), the participant came back to site to have the ABPM device removed. ABPM data collected over the 24-hours was electronically transferred to the central BP laboratory. Systolic blood pressure and diastolic blood pressure were measured at predetermined times every 20 minutes from 06:00 to 21:59, and every 30 minutes from 22:00 to 05:59. For each participant and at each visit (the double-blind withdrawal baseline \[Week 36\] and the week 40) the 24-hour mean SBP (or DBP) was calculated from the area under the SBP (or DBP) time curve. A negative change indicates a decrease in 24-hour mean systolic / diastolic blood pressure from baseline.

Time frame:
From Week 36 (Part 3 double-blind-withdrawal baseline) and Week 40
Reported as:
Least squares mean · mmHg
Changes From Double-blind Withdrawal Baseline (Week 36) to Week 40 of Double-blind-withdrawal (DB-WD) Treatment in 24-hour Mean Systolic (SBP) and Diastolic Blood Pressure (DBP) Measured by Ambulatory Blood Pressure Monitoring
mmHgAprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
24-hour mean systolic blood pressure-0.07 (-1.46 to 1.32)6.46 (5.06 to 7.85)
24-hour mean diastolic blood pressure-0.47 (-1.34 to 0.40)6.28 (5.40 to 7.15)
Statistical analysis
  • Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) vs Placebo in Part 3 (Double-blind Withdrawal) · ANCOVA · p = <0.0001 · Ls mean difference to placebo: -6.53 · 95% CI -8.50 to -4.56
  • Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal) vs Placebo in Part 3 (Double-blind Withdrawal) · ANCOVA · p = <0.0001 · Lsm mean difference to placebo: -6.75 · 95% CI -7.98 to -5.52

Adverse events

Collected over Adverse events (AEs) were considered treatment-emergent, if the onset date is between the first intake of treatment up to 30 days after the stop of study treatment. Study treatment was for up to 48 weeks. In Part 1 double-blind (DB) treatment was for 4 weeks. Part 2 single-blind (SB) study treatment was for 32 weeks. In Part 3 double-blind withdrawal (DB-WD) study treatment was for 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aprocitentan 12.5 mg in Part 1 (Double-blind)1/243 (0.4%)8/243 (3.3%)16/243 (6.6%)
Aprocitentan 25 mg in Part 1 (Double-blind)0/245 (0%)8/245 (3.3%)34/245 (13.9%)
Placebo in Part 1 (Double-blind)0/242 (0%)3/242 (1.2%)5/242 (2.1%)
Aprocitentan 25 mg in Part 2 (Single-blind)9/704 (1.3%)82/704 (11.6%)95/704 (13.5%)
Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)1/310 (0.3%)18/310 (5.8%)6/310 (1.9%)
Placebo in Part 3 (Double-blind Withdrawal)0/303 (0%)9/303 (3%)4/303 (1.3%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Aprocitentan 25 mg in Part 2 (Single-blind)Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
COVID-19 pneumoniaInfections and infestations2/2430/2451/24214/7044/3102/303
Atrial fibrillationCardiac disorders0/2430/2450/2423/7043/3100/303
CellulitisInfections and infestations0/2432/2450/2420/7040/3100/303
Angina unstableCardiac disorders0/2430/2450/2425/7041/3100/303
PneumoniaInfections and infestations1/2431/2450/2422/7042/3100/303
Cardiac failure congestiveCardiac disorders0/2430/2450/2423/7040/3100/303
Peritonsillar abscessInfections and infestations0/2430/2451/2420/7040/3100/303
Pyelonephritis acuteInfections and infestations0/2430/2451/2421/7040/3100/303
SepsisInfections and infestations0/2430/2451/2420/7040/3100/303
Ischaemic strokeNervous system disorders1/2430/2451/2420/7040/3101/303
Most frequent other events
Most frequent other events
EventAprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Aprocitentan 25 mg in Part 2 (Single-blind)Aprocitentan 25 mg in Part 3 (Double-blind Withdrawal)Placebo in Part 3 (Double-blind Withdrawal)
Oedema peripheralGeneral disorders16/24334/2455/24295/7046/3104/303

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
Mean61.2 ± 10.361.7 ± 10.462.2 ± 11.261.7 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
Female999899296
Male144145145434
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
Hispanic or Latino28222373
Not Hispanic or Latino213219218650
Unknown or Not Reported2237
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
American Indian or Alaska Native0000
Asian11141338
Native Hawaiian or Other Pacific Islander1001
Black or African American28282682
White203200202605
More than one race0000
Unknown or Not Reported0134
Region of Enrollment
Region of Enrollment(participants)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
Australia88723
Belgium1348
Canada87621
China6111027
Czechia1031528
Finland95216
France0437
Germany36918
Greece5128
Hungary1416
Israel52310
Italy3205
Lithuania24410
Netherlands2338
Poland15162051
Russia615649166
Spain48618
Ukraine30263086
United Kingdom2013
United States687469211
Body Mass Index at Screening Visit
Body Mass Index at Screening Visit(kg/m^2)Aprocitentan 12.5 mg in Part 1 (Double-blind)Aprocitentan 25 mg in Part 1 (Double-blind)Placebo in Part 1 (Double-blind)Total
Mean33.6 ± 6.234.3 ± 6.833.3 ± 5.633.7 ± 6.2
08

Study locations

159 sites
  • Advanced Cardiovascular, LLC
    Alexander City, Alabama 35010, United States
  • Chrishard Medical Group
    Inglewood, California 90301, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Academic Medical Research Institute Inc
    Los Angeles, California 90022, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • California Kidney Specialists
    San Dimas, California 91773, United States
  • Bay Area Cardiology Associates, P.A.
    Brandon, Florida 33511, United States
  • Century Clinical Research, Inc
    Daytona Beach, Florida 32117, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Canvas Clinical Research, LLC
    Lake Worth, Florida 33467, United States
  • East Coast Institute for Research
    Saint Augustine, Florida 32086, United States
  • Premier Medical Associates
    The Villages, Florida 32159, United States
  • SIU School of Medicine Center for Clinical Research
    Springfield, Illinois 62702, United States
  • Midwest Institute for Clinical Research
    Indianapolis, Indiana 46260, United States
  • Cardiovascular Research of Northwest Indiana, L.L.C.
    Munster, Indiana 46231, United States
  • Reid Physician Associates
    Richmond, Indiana 47374, United States
  • Grace Research, LLC
    Bossier City, Louisiana 71111, United States
  • MedStar Health Research Institute
    Hyattsville, Maryland 20782, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Hypertension and Nephrology Association PA
    Eatontown, New Jersey 07724, United States
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
  • Albany Medical College
    Albany, New York 12206, United States
  • Scott Research Inc
    Laurelton, New York 11413, United States
  • Great Lakes Medical Research LLC
    Westfield, New York 14787, United States
  • Metrolina Internal Medicine/Internal Medicine Research
    Charlotte, North Carolina 28207, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
  • Physician's East Endocrinology
    Greenville, North Carolina 27834, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • University Hospitals Cleveland Medical Center - Neurological Institute
    Cleveland, Ohio 44106, United States
  • Willamette Valley Clinical Studies
    Eugene, Oregon 97404, United States
  • TLM Medical Services LLC
    Columbia, South Carolina 29204, United States
  • DeGarmo Institute of Medical Research
    Greer, South Carolina 29650, United States
  • Stern Cardiovascular Foundation, Inc
    Germantown, Tennessee 38138, United States
  • LifeDOC Research PLLC
    Memphis, Tennessee 38119, United States
  • Amarillo Heart Clinical Research Institute, Inc.
    Amarillo, Texas 79106, United States
  • LinQ Research, LLC
    Pearland, Texas 77584, United States
  • Mercury Clinical Research
    Webster, Texas 77598, United States
  • St. George Kidney Care LLC dba Southern Utah Kidney and Hypertension Center
    Saint George, Utah 84790, United States
  • Burke Internal Medicine & Research
    Burke, Virginia 22015, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Milwaukee Nephrologists, SC
    Wauwatosa, Wisconsin 53226, United States
  • Renal Research
    Gosford, New South Wales 2250, Australia
  • Westmead Hospital Department of Renal Medicine
    Sydney, New South Wales 2145, Australia
  • Baker Heart and Diabetes Institute
    Melbourne, Victoria 3004, Australia
  • Hypertension & Kidney Disease / Huma Neurotransmitter Laboratory
    Melbourne, Victoria 3004, Australia
  • Curtin University, Faculty of Health Sciences, School of Public Health
    Bentley, Western Australia 6102, Australia
  • Royal Perth Hospital Unit - The University of Western Australia
    Perth, Western Australia 6000, Australia
  • Hospital Erasme - Cardiology department
    Brussels, 1070, Belgium
  • Clinique Universitaires de Saint Luc, Departement cardio-vasculaires intensives
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent Cardiologie
    Gent, 9000, Belgium
  • Centre Hospitalier Universitaire du Sart-Tilman
    Liège, 4000, Belgium
  • Manna Research Inc (North Burlington)
    Hamilton, Ontario L8J 3W2, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 2C5, Canada
  • Stephen S. Chow Medicine Professional Corporation
    Toronto, Ontario M4C 5T2, Canada
  • Clinical Research Solutions Inc.
    Waterloo, Ontario N2J 3Z4, Canada
  • The First Affiliated Hospital of Baotou Medical College of Inner Mongolia
    Baotou, 014010, China
  • The Third Xiangya Hospital of Central South University
    Changsha, 410000, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Zhejiang Province People's Hospital
    Hangzhou, 310014, China
  • Hainan NO.3 Provincial people's Hospital
    Sanya, 572000, China
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, 200000, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710061, China
  • FN U Sv.Anny Brno, kardiologická klinika
    Brno, 656 91, Czechia
  • Interni oddeleni, Nefrologie
    Prague, 16000, Czechia
  • Všeobecní fakultní nemocnice Praha
    Praha 2, 128 08, Czechia
  • Thomayerova nemocnice
    Praha 4, 140 59, Czechia
  • Kardio Václavík s.r.o
    Přerov, 750 02, Czechia
  • University of Oulu, Medical Research Center
    Oulu, 90220, Finland
  • TAYS RDI center (Tampere University Hospital,Specialist Internal Medicine, Rare Diseases)
    Tampere, 33520, Finland
  • Turku University Central Hospital - Turun yliopistollinen keskussairaala Sisätautien klinikka
    Turku, 20520, Finland
  • CHU Grenoble - Alpes
    Grenoble cedex 9, 38043, France
  • Hôpital de la Croix-Rousse - Rhône
    Lyon, 69317, France
  • Hôpital Européen Georges Pompidou- Centre d' Investigation Clinique
    Paris, 75015, France
  • Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
    Toulon, 83100, France
  • Jewish Hospital Berlin
    Berlin, 13347, Germany
  • Universitätsklinikum Düsseldorf Klinik für Nephrologie
    Düsseldorf, 40225, Germany
  • Universitätsklinikum Erlangen Klinische Forschungsstation (CRC)
    Erlangen, 91054, Germany
  • Universitätsklinikum des Saarlandes
    Homburg/Saar, 66421, Germany
  • Herzzentrum Leipzig Universitätsklinik für Kardiologie
    Leipzig, 04289, Germany
  • Universitätsklinikum Nürnberg Süd
    Nürnberg, 90471, Germany
  • General Hospital of Athens, Ippokrateio
    Athens, 11527, Greece
  • General Hospital of Athens Georgios Gennimatas
    Athens, 15669, Greece
  • Asklepeion General Hospital
    Athens, 16673, Greece
  • General Hospital Konstantopouleio-Patision
    Nea Ionia, 14233, Greece
  • DRC Gyógyszervizsgáló Központ Kft.
    Balatonfüred, 8230, Hungary
  • Gottsegen György Országos Kardiológiai Intézet
    Budapest, 1096, Hungary
  • Debreceni Egyetem - Klinikai Központ
    Debrecen, 4032, Hungary
  • Markusovszky Egyetemi Oktatókórház
    Szombathely, 9700, Hungary
  • Haemek Medical Center
    Afula, 1834111, Israel
  • Barzilai Medical Center, Cardiovascular Institute
    Ashkelon, 7830604, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Galilee Medical Center
    Nahariya, 2210001, Israel
  • Sheba Medical Center
    Tel HaShomer, 5265601, Israel
  • University Brescia Department Clinical and Experimental Science
    Brescia, 25121, Italy
  • Ospedale San Gerardo, Clinica Medica
    Monza, 20835, Italy
  • Azienda Ospedaliero Universitaria Pisana - Department Clinical and Experimental Medicine
    Pisa, 56126, Italy
  • Azienda Ospedaliera S. Andrea di Roma - Division of Cardiology and of Cardiothoracic and Vascular Science Department -
    Roma, 00189, Italy
  • SCU Medicina Interna e Centro Ipertensione arteriosa. Dipartimento di Scienze Mediche Università di Torino, Aou Citta' Salute E Scienza Torino
    Torino, 10126, Italy
  • JSC "InMedica"
    Kaunas, LT-50177, Lithuania

Showing the first 100 of 159 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallee M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NR, Reid D, Poirier L, Tobe SW; Canadian Hypertension Education Program. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2012 May;28(3):270-87. doi: 10.1016/j.cjca.2012.02.018. PubMed 22595447 ↗
  • Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005 Feb 8;111(5):697-716. doi: 10.1161/01.CIR.0000154900.76284.F6. PubMed 15699287 ↗
  • Danaietash P, Verweij P, Wang JG, Dresser G, Kantola I, Lawrence MK, Narkiewicz K, Schlaich M, Bellet M; PRECISION investigators. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022 Jul;24(7):804-813. doi: 10.1111/jch.14517. Epub 2022 Jun 9. PubMed 35686330 ↗
  • Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Erratum In: Lancet. 2023 Jan 28;401(10373):268. doi: 10.1016/S0140-6736(23)00119-8. PubMed 36356632 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in May 2021, 34 months.

Results were first posted in Mar 2023, 1 year 10 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 34 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2018
First posted
May 30, 2018
StartActual
Jun 18, 2018
Primary completionActual
May 14, 2021
CompletionActual
Apr 25, 2022
Results first posted
Mar 21, 2023
Last update
Mar 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03541174
Responsible party
Sponsor
First posted
May 30, 2018
Start date
Jun 18, 2018
Primary completion
May 14, 2021
Completion
Apr 25, 2022
Results posted
Mar 21, 2023
Last update
Mar 21, 2023

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprocitentan

Start the discussion